News and reporting on BRCA biomarkers.
The draft guidance recommends access to the drug through the Cancer Drugs Fund as maintenance therapy of advanced ovarian, fallopian tube, or primary peritoneal cancer.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
The study has shown that patients on Zejula had longer progression-free survival than those on placebo regardless of their BRCA1/2 mutation or HRD status.
The differing effects of BRCA mutations by tumor lineage could have ramifications for treatments targeting the DNA repair process, the research team said.
A modified analogue of rucaparib is being used to track PARP-1 expression in PARP inhibitor-treated patients with pancreatic, breast, prostate, and other cancer types.
The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.
The PARP inhibitor is approved as a maintenance treatment for advanced ovarian cancer patients who responded to first-line platinum chemotherapy and have BRCA mutations.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Stanford University's Allison Kurian and her colleagues found that women with pathogenic variants were more likely to undergo a bilateral mastectomy.
By profiling hereditary risk variants in women with breast cancer, researchers hope to lay the foundation for future genetic testing programs in the Caribbean country.